Post-operative atrial fibrillation develops in up to 50% of open-heart surgery patients within the first four days after the procedure, doubling mortality risk, quadrupling stroke likelihood, driving a sevenfold increase in acute kidney injury, and extending hospital stays by three to seven days on average. For roughly 45% of those patients it becomes a recurring condition, generating costs that land on the healthcare system, on patients managing ongoing Afib, and on families absorbing what insurance does not cover, with conservative estimates putting the combined U.S. annual tab at roughly $9 billion.
BioXgen is developing a patent-pending cardiac patch derived from extracellular matrix tissue, placed directly on the heart’s surface during surgery before the chest is closed. The patch works through the one-to-four-day window when POAF risk is highest, then resorbs into the surrounding tissue on its own, leaving no permanent foreign material behind and requiring no changes to how surgeons already operate.
Review the full offering and clinical roadmap at invest.bioxgen.life.
This offering is made pursuant to Regulation Crowdfunding. Investing involves risk, including the potential loss of principal. Please review the full offering documents at invest.bioxgen.life before making any investment decision.